ITGR Integer Holdings Corporation

Integer Holdings Corporation Completes Divestiture of Non-Medical Business for $50 Million

Integer Holdings Corporation Completes Divestiture of Non-Medical Business for $50 Million

Electrochem divestiture makes Integer a pure-play medical technology company

PLANO, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced the completion of the previously announced sale of its Electrochem business to Ultralife Corporation for $50 million in cash.

Integer will use the proceeds from the sale to pay down outstanding debt.

“With the divestiture of Electrochem, Integer is now a pure-play medical technology company with additional capital to deploy in high-growth medtech markets,” said Joseph Dziedzic, Integer President & CEO. “I would like to thank the Electrochem team for all their contributions over the years. We think Electrochem has a bright future under the ownership of Ultralife.”

To learn more about Integer, visit .

About Integer®

Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at .

Forward-Looking Statements

Some of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including the statement relating to our use of proceeds from the transaction. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions and actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements, you should carefully consider a number of factors, including, but not limited to, risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release, whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Investor Relations:Media Relations:
Andrew SennKelly Butler
763.951.8312469.731.6617


EN
01/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Integer Holdings Corporation

 PRESS RELEASE

Integer to Present at Piper Sandler Healthcare Conference on Dec. 3, 2...

Integer to Present at Piper Sandler Healthcare Conference on Dec. 3, 2024 PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST. The presentation will be accessible via a . The link to the live webcast may also be accessed under “Ne...

 PRESS RELEASE

Integer Holdings Corporation Completes Divestiture of Non-Medical Busi...

Integer Holdings Corporation Completes Divestiture of Non-Medical Business for $50 Million Electrochem divestiture makes Integer a pure-play medical technology company PLANO, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced the completion of the previously announced sale of its Electrochem business to Ultralife Corporation for $50 million in cash. Integer will use the proceeds from the sale to pay down outstanding debt. “With the divestiture o...

 PRESS RELEASE

Payman Khales to assume the role of Integer Chief Operating Officer an...

Payman Khales to assume the role of Integer Chief Operating Officer and Andrew Senn to become President, Cardio & Vascular in the first quarter of 2025 PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced that Payman Khales will assume the newly created role of Chief Operating Officer during the first quarter of 2025. Andrew Senn will take Mr. Khales’ place as the President, Cardio & Vascular at the same time. Mr. Khales joined the Company in early 20...

 PRESS RELEASE

Integer Holdings Corporation Reports Third Quarter 2024 Results

Integer Holdings Corporation Reports Third Quarter 2024 Results   ~ Continued strong performance with 3Q24 financial results ~~ Raising midpoint of 2024 operating profit and EPS outlook ~ PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three and nine months ended September 27, 2024. Our previously announced sale of the Electrochem business for $50 million in cash remains on track and is expected to close later this month. Except for cash flow measures, prior period amounts have been recast to exclude the Electroch...

Integer Holdings Corp: 3 directors

Three Directors at Integer Holdings Corp sold/sold after exercising options 20,060 shares at between 118.878USD and 123.800USD. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch